Notably, elevated SMYD2 expression was associated with reduced TIDE scores (Figure 5C), collectively suggesting that GC patients with high SMYD2 expression might demonstrate enhanced responsiveness to immunotherapy. This evidence concerns the gene SMYD2 and gastric cancer.